ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SPRY ARS PHARMACEUTICALS INC

休市中 10-02 16:00:00 EDT

4.07

-0.05

-1.21%

盘后4.15

+0.08+1.97%

19:44 EDT

最高4.27	最低3.99	成交量182.87万
今开4.16	昨收4.12	日振幅6.92%
总市值4.05亿	流通市值1.96亿	总股本9,945万
成交额754.01万	换手率3.81%	流通股本4,803万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":4.07,"timestamp":1790971200000,"preClose":4.12,"halted":0,"volume":1828672,"hourTrading":{"tag":"盘后","latestPrice":4.15,"preClose":4.07,"latestTime":"19:44 EDT","volume":49790,"amount":202784.51,"timestamp":1790984648375,"change":0.08,"changeRate":0.019656,"amplitude":0.019656},"delay":0,"changeRate":-0.012135922330097044,"floatShares":48034500,"shares":99447343,"eps":-2.175701,"marketStatus":"休市中","change":-0.05,"latestTime":"10-02 16:00:00 EDT","open":4.16,"high":4.27,"low":3.985,"amount":7540062.68064,"amplitude":0.069175,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.175701,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":4.12,"preHourTrading":{"tag":"盘前","latestPrice":4.3,"preClose":4.12,"latestTime":"09:27 EDT","volume":235,"amount":985.929481,"timestamp":1790947639389,"change":0.18,"changeRate":0.043689,"amplitude":0.07767},"postHourTrading":{"tag":"盘后","latestPrice":4.15,"preClose":4.07,"latestTime":"19:44 EDT","volume":49790,"amount":202784.51,"timestamp":1790984648375,"change":0.08,"changeRate":0.019656,"amplitude":0.019656},"volumeRatio":1.400288898803379,"impliedVol":1.7559,"impliedVolPercentile":0.9163},"requestUrl":"/m/hq/s/SPRY","defaultTab":"news","newsList":[{"id":"1121444252","title":"新闻稿：ARS Pharmaceuticals宣布首席执行官继任计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1121444252","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121444252?lang=zh_cn&edition=full","pubTime":"2026-07-08 04:31","pubTimestamp":1783456303,"startTime":"0","endTime":"0","summary":"致力于赋能高危患者及其护理人员、以更好地预防可能导致过敏性休克的过敏反应的生物制药公司ARS Pharmaceuticals, Inc.今日宣布首席执行官继任计划。联合创始人兼首席执行官理查德·洛温塔尔自2026年7月6日起，将不再担任公司雇员及高管职务。董事会已任命现任总裁唐恩·卡萨莱为首席执行官兼董事，自2026年7月7日起生效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","SPRY","BK4022","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190087573","title":"ARS Pharmaceuticals Inc：2026年现金运营总开支（不含销售成本）下调至2.48亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190087573","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190087573?lang=zh_cn&edition=full","pubTime":"2026-06-25 04:16","pubTimestamp":1782332174,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc 已将其2026年现金运营总开支（不含销货成本）的预期下调至2.48亿美元。这一调整反映了公司对运营效率的持续优化与成本控制措施的强化。通过审慎的财务规划，公司旨在更有效地配置资源，为未来的研发投入和业务拓展创造更有利的财务空间。此举有望提升公司的整体财务健康度与市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116281092","title":"ARS Pharmaceuticals Inc重申Neffy基础业务支持2027年实现现金流盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=1116281092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116281092?lang=zh_cn&edition=full","pubTime":"2026-06-25 04:15","pubTimestamp":1782332113,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc重申，其核心产品Neffy的基础业务，为公司规划了一条在2027年实现现金流盈亏平衡的可行路径。这一表态强化了公司对未来财务表现的信心与具体预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143413101","title":"德鲁·布里斯携手ARS制药，提升严重过敏患者的生活质量意识","url":"https://stock-news.laohu8.com/highlight/detail?id=1143413101","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143413101?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:04","pubTimestamp":1780574686,"startTime":"0","endTime":"0","summary":"前NFL传奇四分卫德鲁·布里斯宣布与生物制药公司ARS Pharmaceuticals合作，共同发起一项旨在提高公众对严重过敏反应认知的倡议。该合作计划将聚焦于那些与严重过敏共存的个体，致力于推广相关的疾病教育，并探讨创新治疗方案如何改善患者的日常生活。布里斯以其卓越的体育生涯闻名，此次跨界合作凸显了他对公共卫生领域的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187836714","title":"ARS Pharmaceuticals：预计多数州级医疗补助计划将在2027年初前将Neffy纳入其无限制药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=1187836714","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187836714?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:06","pubTimestamp":1778839603,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals 预计，到2027年初，大多数州级医疗补助计划将把其药物Neffy纳入其无限制的医疗补助药品目录中。这一进展有望扩大该药物的覆盖范围和患者可及性，对公司未来市场拓展具有积极意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165973837","title":"ARS制药公司：CVS Caremark提案进入最终审批阶段，预计6月初发布明确更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1165973837","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165973837?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:04","pubTimestamp":1778839479,"startTime":"0","endTime":"0","summary":"ARS制药公司宣布，其与CVS Caremark的提案已进入审批流程的最后阶段。公司预计将在6月初提供一份明确的更新信息，以披露该提案的最终结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129690559","title":"ARS Pharmaceuticals任命行业资深人士Donn Casale为总裁，强化领导团队实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1129690559","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129690559?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:03","pubTimestamp":1778673829,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals宣布任命行业资深人士唐·卡萨莱（Donn Casale）为公司总裁，此举旨在进一步强化其领导团队。\n卡萨莱在生物制药领域拥有丰富的管理经验，他的加入将为公司带来宝贵的行业洞见和战略领导力。此次人事任命体现了ARS Pharmaceuticals持续加强其管理层，以推动公司未来发展的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158905047","title":"ARS Pharmaceuticals Inc预计夏季前在加拿大提交Neffy 1毫克用于15-30公斤儿童的审批申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1158905047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158905047?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:09","pubTimestamp":1776247779,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc计划于夏季前向加拿大监管机构提交其Neffy 1毫克产品的审批申请，该产品适用于体重在15至30公斤之间的儿童群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161492576","title":"ARS Pharmaceuticals Inc：Northland Capital 首次覆盖给予“跑赢大盘”评级，目标价25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161492576","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161492576?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:47","pubTimestamp":1775735233,"startTime":"0","endTime":"0","summary":"Northland Capital 近日宣布对 ARS Pharmaceuticals Inc 启动研究覆盖，并给予“跑赢大盘”的积极评级。该机构同时设定了25美元的目标股价，显示出对公司未来增长潜力的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517461243","title":"ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461243","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517461243?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价30.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517398688","title":"Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.01%报10.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517398688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517398688?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:18","pubTimestamp":1741119485,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时18分，Ars Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.01%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041805abe85197&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041805abe85197&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385185","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.57%报10.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385185","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385185?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666704,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，Ars Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.57%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Quoin Pharmaceuticals Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为405.81%、90.91%、50.39%，振幅较大的相关个股有Pds Biotechnology Corporation、天演药业、Syros Pharmaceuticals, Inc.，振幅分别为11.69%、10.10%、10.09%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223144abdf6e9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223144abdf6e9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513377332","title":"Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.16%报10.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513377332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513377332?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:31","pubTimestamp":1740411117,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时31分，Ars Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.16%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为205.96%、86.70%、27.91%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233158a25222ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233158a25222ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510386643","title":"Ars Pharmaceuticals, Inc.盘中异动 快速上涨6.71%报12.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510386643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510386643?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:30","pubTimestamp":1739197823,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时30分，Ars Pharmaceuticals, Inc.股票出现波动，股价急速拉升6.71%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为1449.74%、833.04%、546.45%，振幅较大的相关个股有Solid Biosciences Inc.、Aditxt, Inc.、Impact Biomedical, Inc.，振幅分别为26.04%、6.44%、4.82%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022302398807782&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022302398807782&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509395775","title":"Ars Pharmaceuticals, Inc.盘中异动 快速跳水5.12%报12.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509395775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509395775?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:04","pubTimestamp":1738958695,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日04时04分，Ars Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.12%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.69%。其相关个股中，Conduit Pharmaceuticals Inc.、Surrozen Inc C/Wts 01/08/2031 、Sionna Therapeutics, Inc.涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为8721.92%、183.09%、157.31%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为130.43%、93.55%、56.78%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208040455abc67025&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208040455abc67025&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508141841","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘大幅下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508141841","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508141841?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:40","pubTimestamp":1738593611,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时40分，Ars Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.03%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Cyclerion Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为377.57%、166.64%、60.17%，振幅较大的相关个股有Hcw Biologics Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Invivyd, Inc.，振幅分别为82.17%、33.33%、27.90%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032240119616fd47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032240119616fd47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508399363","title":"Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.11%报13.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508399363","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508399363?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:44","pubTimestamp":1738345446,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日01时44分，Ars Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.11%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.76%。其相关个股中，Metsera, Inc.、Cyclerion Therapeutics, Inc.、180 Life Sciences Corp C/Wts 07/11/2025涨幅较大，Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.、Silexion Therapeutics Corp较为活跃，换手率分别为2607.41%、1985.26%、191.45%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为80.00%、56.30%、55.56%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020101440696150201&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020101440696150201&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506034663","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.29%报14.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506034663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506034663?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:45","pubTimestamp":1737989130,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时45分，Ars Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.29%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Evaxion Biotech As、Pmgc Holdings Inc.较为活跃，换手率分别为893.00%、132.23%、60.70%，振幅较大的相关个股有Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Onconetix, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为65.16%、63.94%、53.97%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272245309874b1f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501272245309874b1f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124761537","title":"异动解读 | 雷蒙德詹姆斯上调评级目标价 ARS Pharmaceuticals股价盘中大涨6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124761537","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124761537?lang=zh_cn&edition=full","pubTime":"2025-01-18 00:38","pubTimestamp":1737131914,"startTime":"0","endTime":"0","summary":"北京时间2025年1月17日,生物制药公司ARS Pharmaceuticals Inc.股价盘中出现大涨,截至收盘,股价上涨6.49%,引发市场广泛关注。据分析,雷蒙德詹姆斯公司在当天发布研报,维持ARS Pharmaceuticals的评级为\"强烈买入\",并将目标价从26美元上调至28美元。ARS Pharmaceuticals是一家专注于开发新型治疗过敏药物的生物技术公司。其旗舰产品Neffy是一种吸收增强型肾上腺素鼻喷雾剂,具有给药快速、携带方便等优势,有望成为替代肾上腺素注射的新型治疗方式。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 雷蒙德詹姆斯上调评级目标价 ARS Pharmaceuticals股价盘中大涨6.49%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SPRY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0025},{"period":"1month","weight":-0.3007},{"period":"3month","weight":-0.5245},{"period":"6month","weight":-0.5096},{"period":"1year","weight":-0.6041},{"period":"ytd","weight":-0.6506}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ARS Pharmaceuticals, Inc.于2016年1月4日根据特拉华州法律成立。该公司是一家生物制药公司，专注于开发新型、可能是一流的候选产品，neffy用于I型过敏反应的紧急治疗，包括过敏反应。neffy是一种肾上腺素的专有组合物，具有一种名为Intravail的创新吸收增强剂，允许neffy以小剂量、易于携带、易于使用、快速给药和可靠的鼻喷雾剂提供注射般的肾上腺素吸收。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.048654},{"month":2,"riseRate":0.5,"avgChangeRate":0.059864},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.043227},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.065084},{"month":5,"riseRate":0.833333,"avgChangeRate":0.033934},{"month":6,"riseRate":0.5,"avgChangeRate":0.05839},{"month":7,"riseRate":0.666667,"avgChangeRate":0.037533},{"month":8,"riseRate":0.5,"avgChangeRate":-0.038936},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.223718},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.026961},{"month":11,"riseRate":0.4,"avgChangeRate":0.043601},{"month":12,"riseRate":0.6,"avgChangeRate":0.080317}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ARS PHARMACEUTICALS INC(SPRY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ARS PHARMACEUTICALS INC(SPRY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}